© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Exact Sciences Corporation (EXAS) stock remained unchanged at $104.91 a share on NASDAQ. The stock opened at $104.91, fluctuating between $104.91 to $104.91 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 20, 2026 | 104.93 | 104.98 | 104.90 | 104.91 | 21.56M |
| Mar 19, 2026 | 103.78 | 103.96 | 103.72 | 103.92 | 1.88M |
| Mar 18, 2026 | 103.81 | 103.96 | 103.75 | 103.75 | 1.5M |
| Mar 17, 2026 | 103.70 | 104.00 | 103.68 | 103.94 | 1.45M |
| Mar 16, 2026 | 103.69 | 103.92 | 103.60 | 103.85 | 2.85M |
| Mar 13, 2026 | 103.53 | 103.69 | 103.45 | 103.57 | 2.5M |
| Mar 12, 2026 | 103.37 | 103.41 | 103.26 | 103.27 | 1.28M |
| Mar 11, 2026 | 103.40 | 103.50 | 103.31 | 103.40 | 1.37M |
| Mar 10, 2026 | 103.60 | 103.69 | 103.33 | 103.37 | 2.61M |
| Mar 09, 2026 | 103.42 | 103.75 | 103.22 | 103.71 | 3.18M |
| Mar 06, 2026 | 103.35 | 103.52 | 103.26 | 103.50 | 1.57M |
| Mar 03, 2026 | 103.21 | 103.46 | 103.10 | 103.37 | 2.8M |
| Mar 02, 2026 | 103.25 | 103.50 | 103.10 | 103.35 | 1.78M |
| Feb 27, 2026 | 103.27 | 103.39 | 102.95 | 103.38 | 2.67M |
| Feb 26, 2026 | 103.29 | 103.35 | 103.20 | 103.25 | 1.91M |
| Feb 25, 2026 | 103.45 | 103.45 | 103.20 | 103.27 | 2.24M |
| Feb 24, 2026 | 103.60 | 103.67 | 103.38 | 103.45 | 2.37M |
| Feb 23, 2026 | 103.50 | 103.65 | 103.37 | 103.39 | 1.53M |
| Feb 20, 2026 | 103.30 | 103.50 | 103.20 | 103.43 | 2.71M |
| Feb 19, 2026 | 103.40 | 103.41 | 103.21 | 103.29 | 1.93M |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
| Employees | 6900 |
| Beta | 1.44 |
| Sales or Revenue | $2.50B |
| 5Y Sales Change% | 2.731% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |